March 18, 2018Open Access

Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment

Key Points

Key points are not available for this paper at this time.

Abstract

These findings suggest that discontinuation of second- or subsequent-line dasatinib after a sustained DMR of ≥ 1 year is feasible, especially for patients with no history of imatinib resistance. In addition, the natural killer cell count was associated with the TFR.

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Okada et al. (Sun,) studied this question.

synapsesocial.com/papers/69d7d1fe11d83f35e5ae2b0c https://doi.org/https://doi.org/10.1016/j.clml.2018.03.004

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial2015 · 300 citations
2Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial2016 · 850 citations
3Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy2010 · 171 citations
4Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.1997 · 1,258 citations
5Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR2010 · 267 citations

Demander à l'IA

Bookmark

View Full Paper